Lipid-based Nanocarriers loaded with Taxanes for the Management of Breast Cancer: Promises and Challenges

2021 ◽  
Vol 22 ◽  
Author(s):  
Nishtha Chaurawal ◽  
Charu Misra ◽  
Kaisar Raza
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast ◽  
Aqueous Solubility ◽  
Lipid Uptake ◽  
Bioavailability Enhancement ◽  
Cancer Management ◽  
Cause Of Deaths ◽  
Breast Cancer Management ◽  
Poorly Soluble ◽  
Efflux Mechanism

: Breast cancer is the leading cause of deaths worldwide among women. Taxanes (most propitious class of diterpenes) have shown dynamic potentials in the treatment of early and metastatic breast cancer. However, challenges like poor bioavailability, low tissue-permeability, compromised aqueous solubility, and dose-dependent side-effects limit the clinical applications of these drugs. Henceforth, to overcome these challenges, various nanotechnology-based drug delivery systems are being explored for the delivery of taxanes in the management of breast cancer. One such promising nanocarrier category is lipid-based nanocarriers, which employ the meritorious features of a variety of lipids, both of natural and synthetic origin. It is also known that lipid uptake plays a significant role in breast cancer cells proliferation and tumor genesis. However, lipid-based nanocarriers could be a great choice to nanoencapsulate the poorly soluble and permeable taxanes for breast cancer management. These systems have an immense promise of bioavailability enhancement, spatial and temporal taxane delivery, improved efficacy, reduced dosing frequency, and even mild inhibition of the P-gp efflux mechanism. Apart from these promises, these carriers are not yet available for the benefit of the end-user. The present review will not only discuss the merits, progress, and promises of these systems but also ponder upon the various challenges faced by these carriers to reach the clinics for the benefit of the patients afflicted with breast cancer.

scholarly journals Management of Breast Cancer in Nepal

2009 ◽  
Vol 48 (175) ◽  
Author(s):  
Yogendra P Singh ◽  
P Sayami
Keyword(s):  
Breast Cancer ◽  
Early Detection ◽  
Cancer Education ◽  
Tumor Biology ◽  
Metastatic Breast ◽  
Premenopausal Women ◽  
Clinical Breast Examination ◽  
Cancer Management ◽  
Breast Cancer Management ◽  
Clinical Breast

Breast cancer is the second most common malignancy among women in Nepal. It is more commonin young premenopausal women. Breast cancer continues to increase in incidence due to lifestylechanges in Nepalese women despite constant remarkable development in the management of thisdisease over the past three decades. Breast cancer was diagnosed solely clinically and surgery wasthe only treatment option until fi fty years ago. Multidisciplinary approach has been adopted fordiagnosis and treatment of breast cancer in Nepal. Imaging is required for the diagnosis, appropriatetreatment decision and proper follow up. Treatment modality depends upon the extent of thedisease and tumor biology. However, there is a strong need for standard guidelines for the propermanagement of breast cancer in Nepal so that surgeries, chemotherapy, hormone therapy andradiotherapy are standardized in the country. Palliative care has been initiated to provide to somepatients with metastatic breast cancer recently.The breast cancer management in Nepal is a little different when compared with the centers in thedeveloped countries. The reasons are socioeconomic status, lack of education and lack of facilities.Although cancer care is on the rise in Nepal, the optimal facility for centers managing breast cancerhas to be improved signifi cantly.Cancer education, screening and early detection are the keyelements to infl uence the diagnosis, treatment and prognosis of breast cancer in Nepal. Breast cancerawareness and clinical breast examination are important tools for early detection in our resourcelimited context. Breast cancer can be cured in majority of the cases if diagnosed in early stages.This review will focus on relevant patient data along with future recommendation regarding breastcancer treatment in Nepal.Key Words: Breast cancer, cancer education, chemotherapy, imaging, radiotherapy, surgery

PP-8-34 Metastatic breast cancer management in France

1996 ◽  
Vol 32 ◽  
pp. 55
Author(s):  
R. Launois ◽  
J. Reboul-Marty ◽  
B. Henry ◽  
P. Aussage ◽  
M.L. Abella ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Cancer Management ◽  
Breast Cancer Management

Recent Advances in the Systemic Management of Metastatic Breast Cancer

2002 ◽  
Vol 15 (1) ◽  
pp. 52-61 ◽  
Author(s):  
Laura Boehnke Michaud ◽  
Kellie L. Jones
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
The United States ◽  
Similar Efficacy ◽  
Synergistic Activity ◽  
Cancer Management ◽  
Breast Cancer Management ◽  
Chemotherapy Agents ◽  
The Way

Although improvements in breast cancer management have been made, many women are diagnosed with metastatic breast cancer, an incurable stage of the disease. Several new therapies have become available over the past years that have changed the way we manage metastatic breast cancer. The new aromatase inhibitors, anastrozole, letrozole, and exemestane, are potent agents in this fight. Anastrozole and letrozole have been shown to produce superior efficacy and tolerability compared with tamoxifen as first-line endocrine therapy for metastatic breast cancer. Exemestane is being compared with tamoxifen in a similar manner, but results are pending. Trastuzumab is a monoclonal antibody directed against the HER2 oncogene with intrinsic antitumor activity and synergistic activity with traditional chemotherapy. Newer combinations with trastuzumab are also changing the way we administer other chemotherapy agents in patients who overexpress this oncogene. Traditional chemotherapy has also changed over the recent past and now includes an oral agent, capecitabine, for the treatment of metastatic breast cancer. Epirubicin, an anthracycline new to the United States, appears to have similar efficacy and toxicity to doxorubicin, with dosing issues being quite important. With all of these new agents within our grasp, there is hope for all patients with metastatic breast cancer.

scholarly journals Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival

2014 ◽  
Vol 8 ◽  
pp. BCBCR.S9032 ◽  
Author(s):  
Joseph J. Maly ◽  
Erin R. Macrae
Keyword(s):  
Breast Cancer ◽  
Kinase Inhibitors ◽  
Metastatic Breast ◽  
Progression Free Survival ◽  
Preclinical Research ◽  
Her2 Positive ◽  
Cancer Management ◽  
Improved Outcomes ◽  
Breast Cancer Management ◽  
Computer Based

Tyrosine kinase inhibitors have revolutionized the oncology community and were pioneered by the use in HER2-targeted therapies. Improved outcomes were seen with the advent of trastuzumab, leading investigators to develop newer agents to target the HER2 pathway such as the novel monoclonal antibody pertuzumab. In this paper, we describe the attributes of pertuzumab including: mechanism of action, pharmacokinetics and metabolism, safety/cardiotoxicity, drug interactions, efficacy, and role in HER2-positive breast cancer management. Newly reviewed here versus previously published reviews on pertuzumab oriented therapy are data of pertuzumab monotherapy as it is used in combination with other anti-HER2 agents derived from preclinical research and ongoing clinical trials. Materials and Methods A computer based literature search was carried out using PubMed data reported at international meetings (ASCO) up to September 2013 were included.

Review of Clinical Studies of CA 27.29 in Breast Cancer Management

1999 ◽  
Vol 14 (1) ◽  
pp. 36-39 ◽  
Author(s):  
R.A. Beveridge
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Critical Review ◽  
Early Stage ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Review Of The Literature ◽  
Cancer Management ◽  
Breast Cancer Management

A critical review of CA 27.29 and CA 15-3 is performed in this paper. A review of the literature is undertaken. A review of the FDA submissions for 27.29 for both early stage and monitoring metastatic breast cancer patients is reviewed.

scholarly journals Use of Liposomal Doxorubicin for Metastatic Breast Cancer Management Across Europe: Results of Eos (European Observatory & Survey)

2014 ◽  
Vol 25 ◽  
pp. iv130
Author(s):  
V. Lorusso ◽  
A. Śmiałowska-Janiszewska ◽  
K. Krzemieniecki ◽  
S. Antolín Novoa ◽  
F. Mefti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Liposomal Doxorubicin ◽  
Metastatic Breast ◽  
Cancer Management ◽  
Breast Cancer Management
Sign in / Sign up

Export Citation Format

Share Document